Replies to post #417657 on Amarin Corp Plc (AMRN)

[Number sleven]

Bouf, As long as the courts interpret the Hatch Waxman act, as an act that negates method of use patents there is no way to keep them out of the US market. The generic companies have been unable to take the US market for CVD. Not for lack of trying. Their presence has damaged the market and prevented growth.
Sleven,

[Pharmacydude]

Bouf
Outside the US the chemical IPE has regulatory exclusivity. The US relies on “method of use patents” which the courts don’t recognize or enforce.
EU will only have Vascepa until at least 2031 (I believe)